Show simple item record

dc.contributor.authorGlavey, S V
dc.contributor.authorManier, S
dc.contributor.authorClauser, K
dc.contributor.authorTahri, S
dc.contributor.authorPark, J
dc.contributor.authorReagan, M R
dc.contributor.authorMoschetta, M
dc.contributor.authorMishima, Y
dc.contributor.authorGambella, M
dc.contributor.authorRocci, A
dc.contributor.authorSacco, A
dc.contributor.authorO'Dwyer, M E
dc.contributor.authorAsara, J M
dc.contributor.authorPalumbo, A
dc.contributor.authorRoccaro, A M
dc.contributor.authorGhobrial, I M
dc.contributor.authorNaba, Alexandra
dc.contributor.authorHynes, Richard O
dc.date.accessioned2018-07-31T13:14:28Z
dc.date.available2018-07-31T13:14:28Z
dc.date.issued2017-03
dc.date.submitted2016-12
dc.identifier.issn0887-6924
dc.identifier.issn1476-5551
dc.identifier.urihttp://hdl.handle.net/1721.1/117210
dc.description.abstractThe extracellular matrix (ECM) is a major component of the tumor microenvironment, contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In multiple myeloma (MM), interactions between MM cells and the bone marrow (BM) microenvironment, including the BM ECM, are critical to the pathogenesis of the disease and the development of drug resistance. Nevertheless, composition of the ECM in MM and its role in supporting MM pathogenesis has not been reported. We have applied a novel proteomic-based strategy and defined the BM ECM composition in patients with monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed and relapsed MM compared with healthy donor-derived BM ECM. In this study, we show that the tumor ECM is remodeled at the mRNA and protein levels in MGUS and MM to allow development of a permissive microenvironment. We further demonstrate that two ECM-affiliated proteins, ANXA2 and LGALS1, are more abundant in MM and high expression is associated with a decreased overall survival. This study points to the importance of ECM remodeling in MM and provides a novel proteomic pipeline for interrogating the role of the ECM in cancers with BM tropism.en_US
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttps://doi.org/10.1038/leu.2017.102en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceProf. Hynes via Courtney Crummetten_US
dc.titleProteomic characterization of human multiple myeloma bone marrow extracellular matrixen_US
dc.typeArticleen_US
dc.identifier.citationGlavey, S. V. et al. “Proteomic Characterization of Human Multiple Myeloma Bone Marrow Extracellular Matrix.” Leukemia 31, 11 (March 2017): 2426–2434en_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.approverHynes Richarden_US
dc.contributor.mitauthorNaba, Alexandra
dc.contributor.mitauthorHynes, Richard O
dc.relation.journalLeukemiaen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsGlavey, S V; Naba, A; Manier, S; Clauser, K; Tahri, S; Park, J; Reagan, M R; Moschetta, M; Mishima, Y; Gambella, M; Rocci, A; Sacco, A; O'Dwyer, M E; Asara, J M; Palumbo, A; Roccaro, A M; Hynes, R O; Ghobrial, I Men_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0001-7603-8396
mit.licensePUBLISHER_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record